Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William Watt is active.

Publication


Featured researches published by William Watt.


Biochimica et Biophysica Acta | 2010

Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors.

Zhigang Wang; William Watt; Nathan A. Brooks; Melissa S. Harris; Jan Urban; Douglas P. Boatman; Michael McMillan; Michael Kahn; Robert L. Heinrikson; Barry C. Finzel; Arthur J. Wittwer; James Robert Blinn; Satwik Kamtekar; Alfredo G. Tomasselli

Because of their central role in programmed cell death, the caspases are attractive targets for developing new therapeutics against cancer and autoimmunity, myocardial infarction and ischemic damage, and neurodegenerative diseases. We chose to target caspase-3, an executioner caspase, and caspase-8, an initiator caspase, based on the vast amount of information linking their functions to diseases. Through a structure-based drug design approach, a number of novel beta-strand peptidomimetic compounds were synthesized. Kinetic studies of caspase-3 and caspase-8 inhibition were carried out with these urazole ring-containing irreversible peptidomimetics and a known irreversible caspase inhibitor, Z-VAD-fmk. Using a stopped-flow fluorescence assay, we were able to determine individual kinetic parameters of caspase-3 and caspase-8 inhibition by these inhibitors. Z-VAD-fmk and the peptidomimetic inhibitors inhibit caspase-3 and caspase-8 via a three-step kinetic mechanism. Inhibition of both caspase-3 and caspase-8 by Z-VAD-fmk and of caspase-3 by the peptidomimetic inhibitors proceeds via two rapid equilibrium steps followed by a relatively fast inactivation step. However, caspase-8 inhibition by the peptidomimetics goes through a rapid equilibrium step, a slow-binding reversible step, and an extremely slow inactivation step. The crystal structures of inhibitor complexes of caspases-3 and -8 validate the design of the inhibitors by illustrating in detail how they mimic peptide substrates. One of the caspase-8 structures also shows binding at a secondary, allosteric site, providing a possible route to the development of noncovalent small molecule modulators of caspase activity.


Tetrahedron Letters | 1995

A novel asymmetric synthesis of atropisomeric 6-aryl pyrazinones via an unusual chirality transfer process. New chiral ligands for the GABAA/Chloride ionophore complex

John Tulinsky; Stephen A. Mizsak; William Watt; Lester A. Dolak; Thomas M. Judge; Ronald B. Gammill

Abstract Cyclization of ( S , S )- α -[(1-phenylethyl)amino]- α -(2-iodophenyl)acetonitrile 3a with (COCl) 2 in toluene or chlorobenzene afforeded the atropisomeric pyrazinone ( aS , S ) 6-(2-α-iodophenyl)-3,5-dichloro-1-(1-phenylethyl)-2(1H)-pyrazinone 7a in 57% yield. With smaller ortho substituents, mixtures of atropisomers were obtained. Stereochemical assignments were made via X-Ray and NOE experiments.


Bioorganic & Medicinal Chemistry Letters | 1995

Chiral spirocyclic benzopyran potassium channel openers: Evidence for the active conformation of levcromakalim

R.C. Gadwood; L.M. Thomasco; V.E. Groppi; B.-A. Burnett; S.J. Humphrey; M.P. Smith; William Watt

Abstract Both enantiomers of a spirocyclic benzopyran imidazolone were prepared in high enantiomeric purity. The S-isomer was found to be a potent potassium channel opener while the R-isomer was completely inactive. Comparison of this structurally rigid compound with levcromakalim suggests that the biologically active conformation of levcromakalim is the same as its preferred conformation in solution and solid state.


Structure | 1999

The atomic-resolution structure of human caspase-8, a key activator of apoptosis.

William Watt; Kenneth A. Koeplinger; Ana M. Mildner; Robert L. Heinrikson; Alfredo G. Tomasselli; Keith D. Watenpaugh


Journal of Medicinal Chemistry | 1986

Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues

Suvit Thaisrivongs; Donald T. Pals; Warren M. Kati; Steve R. Turner; Lisa M. Thomasco; William Watt


Journal of Medicinal Chemistry | 2003

Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.

Michael R. Barbachyn; Gary J. Cleek; Lester A. Dolak; Stuart A. Garmon; Joel Morris; Eric P. Seest; Richard C. Thomas; Dana S. Toops; William Watt; Donn G. Wishka; Charles W. Ford; Gary E. Zurenko; Judith C. Hamel; Ronda D. Schaadt; Douglas Stapert; Betty H. Yagi; Wade J. Adams; Janice M. Friis; J. Gregory Slatter; James P. Sams; Nancee L. Oien; Matthew J. Zaya; Larry C. Wienkers; Michael A. Wynalda


Journal of Medicinal Chemistry | 1993

Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers

Robert C. Gadwood; Bharat V. Kamdar; Loretta A. Cipkus Dubray; Mark L. Wolfe; Michael P. Smith; William Watt; Stephen A. Mizsak; Vincent E. Groppi


Journal of Organic Chemistry | 1998

Stereoselective Synthesis of Furo[2,3-c]pyridine Pyrimidine Thioethers, A New Class of Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

Donn G. Wishka; David R. Graber; Eric P. Seest; Lester A. Dolak; Fusen Han; William Watt; Joel Morris


Journal of the American Chemical Society | 1992

Furans in synthesis. XXI: Total syntheses of (±)- and (-)-fastigilin C

Steven P. Tanis; Edward D. Robinson; Mark C. McMills; William Watt


Bioorganic & Medicinal Chemistry Letters | 2003

The effect of remote chirality on the antibacterial activity of indolinyl, tetrahydroquinolyl and dihydrobenzoxazinyl oxazolidinones.

Fred L. Ciske; Michael R. Barbachyn; Michael J. Genin; Kevin C Grega; Chi-Sing Lee; Lester A. Dolak; Eric P. Seest; William Watt; Wade J. Adams; Janice M. Friis; Charles W Ford; Gary E Zurenko

Collaboration


Dive into the William Watt's collaboration.

Researchain Logo
Decentralizing Knowledge